Vemurafenib (ZELBORAF, Hoffmann-La Roche Inc; Figure 1) is a first-in-class selective inhibitor of the BRAF serine-threonine kinase, FDA approved for the treatment of metastatic melanoma harboring ...
Our work on the gene and the structure of the BRAF protein underpinned the discovery of drugs that target BRAF such as vemurafenib and dabrafenib, which have been recommended for use on the NHS. Photo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback